Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Immune Infiltration and Prostate Cancer

Amy Strasner, Michael Karin

Frontiers in Oncology · 2015 · Review

doi:10.3389/fonc.2015.00128

Abstract

It is becoming increasingly clear that inflammation influences prostate cancer (PCa) development and that immune cells are among the primary drivers of this effect. This information has launched numerous clinical trials testing immunotherapy drugs in PCa patients. The results of these studies are promising but have yet to generate a complete response. Importantly, the precise immune profile that determines clinical outcome remains unresolved. Individual immune cell types are divided into various functional subsets whose effects on tumor development may differ depending on their particular phenotype and functional status, which is often shaped by the tumor microenvironment. Thus, this review aims to examine the current knowledge regarding the role of inflammation and specific immune cell types in mediating PCa progression to assist in directing and optimizing immunotherapy targets, regimens, and responses and to uncover areas in which further research is needed. Finally, a summary of ongoing immunotherapy clinical trials in PCa is provided.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Prostate cancer (PCa) is the most common non-cutaneous cancer and second leading cancer-related cause of death of men in the United States.. Localized PCa can be controlled with surgery or radiation over 80% of the time. If prostate tumors are metastatic at presentation, neither surgery nor radiation will confer significant clinical benefit and androgen deprivation therapy (ADT) represents the sole therapeutic option for such patients. Unfortunately, resistance to hormonal targeting develops in most patients within 2 years, a state that is termed metastatic castration-resistant PCa (mCRPC) and is virtually untreatable. Until recently, Docetaxel was the lone accepted remedy for mCRPC and was associated with a 2- to 3-month enhancement of survival. The advent of newer chemotherapeutic agents such as cabazitaxel and approval of next generation drugs abiraterone and enzalutamide have improved upon this effect, yet resistance ultimately ensues, possibly via mutations in the androgen receptor (AR) gene.

Relative to other forms of cancer, the discovery of valuable predictive markers of disease progression has been particularly challenging for PCa. Genetic markers capable of identifying clinically aggressive disease remain elusive. In addition, PCa is unique among solid tumors in that imaging techniques are insufficient for definitive identification and diagnosis of malignancy. Instead, the pre-biopsy serum prostate specific antigen (PSA) value is used as an indicator of potential underlying disease, but the utility of this screening method has been intensely scrutinized. In fact, the United States Preventative Services Task Force (USPSTF) recently recommended against routine PSA screening. Importantly, the ramifications of this ruling may be an increase in the proportion of men diagnosed at later stages of PCa. Thus, the identification of novel therapeutic targets for and biomarkers of mCRPC is severely needed.

A multitude of studies investigating alternative PCa treatment interventions or predictive markers have focused on components of the inflammatory response, with promising results. A relationship between inflammation and cancer was first proposed by Virchow in 1863 and chronic inflammation is now well accepted as a driving force behind many malignancies, such as gastric, colon, esophageal and lung cancers, and hepatocellular carcinoma. While the role of the immune system in PCa is less clear, it has been implicated both as a possible etiologic agent and a tumor promoter. A recent report from the REDUCE study suggesting that aspirin and/or NSAID use decreased risk of PCa in men with a negative biopsy supports this notion. This review will explore the evidence regarding immune infiltration as a potential mediator and indicator of aggressive PCa, as well as a target for PCa therapeutics. Because this topic has been comprehensively evaluated elsewhere, only recent literature will be addressed here.

Prostatitis and Prostate Cancer: The Evidence

As with many other cancers, PCa arises from accumulation of acquired genetic and epigenetic alterations. Currently, age, ethnicity, and family history are the only known risk factors for development of prostate neoplasia. These genetic traits may partially explain the geographical variance in PCa incidence and mortality, with rates in Southeast and East Asia being much lower than those in the United States and Western Europe. By contrast, the elevated rate of PCa observed in Chinese and Japanese men within one generation of relocation to the West indicates that environmental factors, particularly lifestyle factors such as diet, also contribute to the emergence of PCa. One likely link between environmental stimuli and PCa occurrence is chronic inflammation. Support for this hypothesis comes from reports of focal atrophic lesions in the prostate containing a relatively high percentage of proliferating epithelial cells and acute or chronic inflammatory infiltrate. These areas, designated proliferative inflammatory atrophy (PIA), comprise an extensive portion of the peripheral zone of the prostate, the primary site where PCa originates, and have been suggested to be precursors of prostatic intraepithelial neoplastic (PIN) lesions, although one recent retrospective epidemiological study refuted this concept. Additional evidence comes from a recent meta-analysis assessing 20 case–control studies conducted between 1990 and 2012 that revealed a significant positive relationship between self-reported prostatitis and PCa. However, the authors were unable to demonstrate a causal link between the two due to the absence of cohort studies in this analysis. Numerous other epidemiological investigations have examined the connection between prostatitis and subsequent PCa risk and while early studies described an elevated risk of malignancy or recurrence due to presence of inflammation, subsequent studies have produced conflicting results. In addition to differences in study populations and potential selection and other forms of bias, plausible explanations for these inconsistencies include tissue sample size and composition, definition and measurement of inflammation, tissue regions assessed, and categories of prostatitis examined. In order to obtain a more accurate reflection of the relationship between prostatitis and PCa, improved standardization of these measurements, incorporation of asymptomatic inflammatory prostatitis, and a prospective design in future epidemiological studies are needed. Importantly, many investigations defined inflammation with discrete variables, such as present or absent or severe, moderate or mild rather than with a detailed analysis of the cellular composition and distribution of the infiltrate. Although this classification system may be obligatory for certain statistical analyses, it is a major limitation of these investigations and may be masking true associations that exist. Furthermore, these studies may benefit from experimental research designed to provide insight regarding the kinetics, distribution, type, and components of inflammation that are important for prostate tumorigenesis.

Despite the abundance of data evaluating the connection between prostatitis and PCa, the sources of prostatic inflammation have yet to be fully elucidated. Proposed causes can be divided into three broad categories: (1) microorganism induced, including E. coli, Propionibacterium acnes, and those associated with urine reflux and sexually transmitted diseases, (2) non-microorganism induced, such as uric acid crystals formed during urine reflux, estrogen, dietary factors, especially heterocyclic amines (HCA) 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) generated from cooking meats at high temperatures, obesity, and physical trauma such as corpora amylacea, and (3) treatment- or tumor-elicited inflammation.

Some of these hypotheses were tested using mouse models. For example, Shinohara et al. reported that intraurethral inoculation of mice with a prostatectomy-derived strain of P. acnes elicited prolonged and lobe-specific severe acute and chronic inflammation that was associated with increased proliferation and reduced Nkx3.1 and AR expression. Inflammatory infiltrate consisted of luminal neutrophils and stromal mononuclear cells. Similar observations were noted in experiments using E. coli. Introduction of this bacterium into mouse urogenital tracts provoked a dramatic decline in Nkx3.1 and AR expression and a corresponding enhancement of proliferation as well as the basal cell marker p63. These changes were pursuant to an early influx of neutrophils into prostatic lumen and stroma followed by a surge in stromal mononuclear cells and later a marked increase in plasma cells. Upregulation of pro-inflammatory genes, including IL-6 and COX-2, was also detected using a comparable system. The effects of these events on PCa pathogenesis were examined by combining bacteria CP9-induced prostatitis and a mouse PCa model and revealed that tissue damage resulting from acute prostatitis facilitates accumulation of stromal α-smooth muscle actin-positive myofibroblasts and the conversion of basal cells into luminal cells, which accelerates PCa progression.

Non-bacterial inflammatory stimuli were also evaluated with respect to PCa development. A novel model of prostatitis involving ubiquitous overexpression of aromatase (AROM+) in mice exhibited early and persistent prostatic mast cell infiltration with subsequent accumulation of neutrophils, T lymphocytes, and macrophages, as well as increased expression of numerous chemokines. This chronic inflammation preceded formation of PIN lesions containing and surrounded by immune cells. Finally, Birbach et al. expressed a constitutively active form of the inflammatory mediator IκB kinase 2 in prostate epithelium of mice harboring a heterozygous Pten deletion and detected a robust inflammatory response, primarily encompassing neutrophils and macrophages in the prostate, that was accompanied by increased tumor size due to enhanced epithelial and stromal proliferation, generation of cribiform structures and stromal remodeling, but no invasion or metastasis.

Together, these data corroborate the ability of inflammatory stimuli to generate an immune response that modulates the local environment into one that is conducive to malignant transformation and progression and implicate chronic inflammation as a causative factor in PCa. More studies combining prostatitis and murine PCa models are needed to confirm these effects and determine the mechanisms by which these agents promote disease. Of course, these results also must be confirmed in humans.

Immune Cells and Prostate Cancer: Friends or Foes?

As previously described, epidemiological studies exploring the relationship between prostatitis and PCa development may be limited by the absence of characterization of cellular phenotypes displayed by tumor-infiltrating leukocytes (TIL). However, many studies assessing the association between specific immune cells and PCa are now available and those conducted between 2008 and 2014 are summarized according to cell type in Table 1. Most of these investigated CD3+, CD4+, or CD8+ cells in prostatectomy or biopsy tissue of PCa patients and found such cells to be pro-tumorigenic. For example, a cross-sectional study of lymphocyte infiltration in tumor tissue microarrays from patients with PSA recurrence reported that extremely high or low CD3+ cell counts were correlated with reduced PSA recurrence-free survival (RFS). Importantly, CD3 was the only T-cell marker included in this study and no evaluations of T-cell subsets were performed. Thus, the variation in clinical outcomes across CD3+ cell quartiles may at least partially reflect differences in T-cell populations. In fact, the authors mentioned unpublished data indicating that higher numbers of regulatory T-cells (Treg) were associated with more advanced tumor stage and PSA-RFS. A likely assumption is that the CD3+ cells whose low numbers conferred poor prognoses were protective in nature. Thus, it is critical to determine not only the cell type but also the subtype associated with different outcomes in order to better direct therapeutic efforts. By contrast, the spontaneous TRAMP mouse PCa model was used to illustrate that the trafficking of a naturally arising clonally expanded PCa histone H4-specific population of CD44+CD8+ T-cells to prostate tissue lessened tumor burden but failed to improve survival. Several possible explanations for the lack of survival impact exist. First, it may be that the anti-tumorigenic CTL were initially successful in eliminating tumor cells but were eventually rendered inactive by a suppressive tumor microenvironment. Alternatively, it is conceivable that the antigen-specific destruction of H4-expressing tumor cells selected for less immunogenic and possibly more adept H4-negative tumor cells, or instead, that this response exerted pressure on cancer cells to downregulate MHC or undergo immunoediting of tumor antigens and thereby escape immune recognition and destruction. In line with the former hypothesis, several investigations demonstrated that tumor-infiltrating CTL expressed PD-1, one of several indicators of T-cell exhaustion, in PCa patients. This is an essential consideration for immunotherapeutic efforts and emphasizes the importance of evaluating both the cellular subtype and functional status when assessing TIL.

Another cell type that has received much attention and shown relatively consistent results in the context of PCa progression is the tumor-associated macrophage (TAM). All studies analyzed demonstrated a pro-tumorigenic effect of TAM, although one report specified that this was true only for M2 type macrophages. However, only a fraction of the literature displayed a link between TAM and recurrence. In particular, Nonomura et al. determined TAM count to be a significant prognostic factor of clinical outcome in PCa patients. A second study that found TAM to be related to recurrence indicated this to be true only in the control but not ADT treated group. Thus, TAM count may be a good biomarker for disease progression, but further research is needed to identify the specific subset of macrophages and PCa patients for which this is applicable. TAM may also represent a viable therapeutic target for PCa, as demonstrated by Escamilla et al., who showed a reduction in castration-induced recruitment of pro-tumorigenic TAM and delayed emergence of CRPC in a mouse Myc-CaP PCa model following CSF1R inhibition.

As expected, presence of immunosuppressive immune cells, such as Treg, myeloid derived suppressor cells (MDSC), and according to one report, TH17 cells, in prostate tissue was suggestive of more aggressive disease, but surprisingly few studies were able to equate this with clinical prognosis. Neutrophils and mast cells have also been fairly well studied, but investigations involving both cell types have generated conflicting results concerning their influence on PCa. One source of contention may concern the area of tissue evaluated. This point is nicely illustrated by Johannson et al., who implicated peritumoral but not intratumoral mast cells as independent prognostic variables of PCa progression. In addition, work from Pittoni et al. emphasized that care must be taken to evaluate potential negative outcomes when manipulating immune cell populations with therapies. In the TRAMP model of murine PCa, targeting mast cells prevented growth of well-differentiated tumors but simultaneously stimulated progression of more aggressive, neuroendocrine type tumors. Similarly, Tang et al. observed a late IL-2-induced expansion of Treg following castration and immunization that negated the initial anti-tumorigenic CD8+ T-cell response.

Relative to other immune cells, B cells have been generally overlooked in terms of PCa. However, the importance of these cells in PCa progression was established in a landmark and subsequent papers using subcutaneous Myc-CaP and spontaneous TRAMP mouse PCa models to show that castration-induced cell death and resulting hypoxia stimulated CXCL13-mediated infiltration of lymphotoxin β (LTb)-expressing B lymphocytes into regressing tumors. These cells subsequently activated IKKα, STAT3 and BMI1 in cancer cells to promote CRPC progression. Notably, interference with any aspect of this pathway delayed emergence of hormone-resistant tumors. These initial findings were extended to reveal that the identical mechanism operates in androgen-dependent regeneration of normal prostate progenitor cells. Interestingly, an independent investigation reported significant reductions in human and murine PCa tumor growth following combination therapy with HIF-1α and phospho-STAT3 inhibitors. Together, these data suggest that the B cell response to tissue injury or death following androgen depletion drives restorative or aberrant proliferation in the prostate. In addition, a recent report implicates immunosuppressive IgA+PD-L1+IL-10+ plasma cells in impeding response to low-dose chemotherapy in a T-cell-dependent manner. The presence of CD20+ B cells has been documented in human PCa as well, and the density of these cells was shown to be higher in malignant than benign tissue. Furthermore, a case study of an advanced PCa patient treated with the B cell depleting antibody Rituximab produced fairly encouraging results. A Phase 0 clinical trial evaluating Rituximab as neoadjuvant therapy in patients prior to radical prostatectomy is currently ongoing. Thus, although research is still in preliminary stages, B cells may represent an emerging target for PCa immunotherapeutics. However, it is likely that a damage response and/or an immunogenic stimulus is needed to make these cells relevant in prostate carcinogenesis or that only particular subsets, such as those expressing LTβ, or IgA are crucial.

Prostate Cancer and Immunotherapy

The emergence of immune cells as important mediators of PCa progression has spawned a multitude of clinical trials targeting these cells via different approaches, including therapeutic vaccines, checkpoint inhibitors/immune modulators, adoptive T-cell therapy, and monoclonal antibodies. In theory, PCa should be particularly conducive to this type of treatment due to its long latency period. However, because PCa is commonly diagnosed late in life, therapeutic vaccines may not be as efficacious as desired due to the age-related decline in immune responsiveness. Despite this fact, Sipuleucel-T was the first immunotherapy approved by the FDA for PCa and has shown an overall survival advantage in mCRPC patients, although no effect on progression-free survival was noted. The lack of short-term response observed in this study may at least partially be partially attributed to the fact that immunotherapeutic agents are not directly cytotoxic, as are more standard treatments. Due to space limitations, individual studies will not be discussed in detail here but are summarized in Table 2. One important message from the combined studies is that, while extremely promising, these immunotherapeutic methodologies still need to be optimized as no individual treatment has yet elicited a complete response. Complete and durable responses will likely require combinations of current immunotherapy and/or more standard approaches, such as chemotherapy, radiation, or ADT, which induce an immunogenic stimulus or enhance T-cell responses. In addition, ideal target patient populations and treatment protocols still need to be identified. For example, a study combining PROSTVAC and ipilimumab discovered that patients with lower PD-1+Tim-3NEGCD4EM, higher PD-1NEGTim-3+CD8+, and more CTLA-4NEG Treg at baseline survived longer. Furthermore, an increase in Tim-3+ natural killer cells following vaccination conferred survival benefits. Similarly, Klyushnenkova et al. illustrated the importance of breaking immunological tolerance to “self” antigen by targeting CD25+ Treg during CTLA-4 blockade in mice. Although this research has several shortcomings, it highlights the potential value of such combination therapies.

Summary

The presence of inflammatory cells in the prostate is well documented. Evidence suggests that these cells may drive PCa development. Additionally, growing tumors can induce recruitment of immune cells into the prostate microenvironment and initiate a reciprocal interaction that promotes disease progression. Surprisingly, information regarding precise profiles of prostate tumor-infiltrating leukocytes is extremely limited. Individual cells and the overall immune response have the potential to be anti- or pro-tumorigenic, depending on cellular phenotypes, combinations, localization and the tumor microenvironment. Thus, the identities, traits, functional status, distribution, kinetics, and interactions of inflammatory cells in the prostate and PCa must be fully characterized in order to elevate and combine the already promising current immunotherapies. Furthermore, efforts must be directed at elucidating better indicators of potential response to facilitate identification of ideal target populations, as well as biomarkers to assess therapeutic efficacy. Progress in these areas will strengthen the existing optimism that immunotherapy will become part of a successful standard care regimen for future PCa patients.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 95

  1. 1.

    Siegel R Ma J Zou Z Jemal A Cancer statistics, 2014. CA Cancer J Clin (2014 ) 64:9–29.

    Not in our library10.3322/caac.21208

  2. 2.

    Uhlman MA Bing MT Lubaroff DM. Prostate cancer vaccines in combination with additional treatment modalities. Immunol Res (2014 ) 59:236–42.

    Not in our library10.1007/s12026-014-8532-1

  3. 3.

    Kantoff PW Carroll PR D’Amico AV, editors. Prostate Cancer: Principles and Practice. Philadelphia, PA: Lippincott William & Wilkins (2002 ).

    Not in our library

  4. 4.

    Berthold DR Pond GR Soban F de Wit R Eisenberger M Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008 ) 26:242–5.

    Not in our library10.1200/jco.2007.12.4008

  5. 5.

    Petrylak DP Tangen CM Hussain MH Lara PN Jr Jones JA Taplin ME Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004 ) 351:1513–20.

    Not in our library10.1056/nejmoa041318

  6. 6.

    Tannock IF de Wit R Berry WR Horti J Pluzanska A Chi KN Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004 ) 351:1502–12.

    Not in our library10.1056/nejmoa040720

  7. 7.

    Basch E Autio K Ryan CJ Mulders P Shore N Kheoh T Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013 ) 14:1193–9.

    Not in our library10.1016/s1470-2045(13)70424-8

  8. 8.

    de Bono JS Logothetis CJ Molina A Fizazi K North S Chu L Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011 ) 364:1995–2005.

    Not in our library10.1056/nejmoa1014618

  9. 9.

    Scher HI Fizazi K Saad F Taplin ME Sternberg CN Miller K Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012 ) 367:1187–97.

    Not in our library10.1056/nejmoa1207506

  10. 10.

    Schrader AJ Boegemann M Ohlmann CH Schnoeller TJ Krabbe LM Hajili T Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2014 ) 65:30–6.

    Not in our library10.1016/j.eururo.2013.06.042

  11. 11.

    Culig Z. Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother (2014 ) 15:1427–37.

    Not in our library10.1517/14656566.2014.915313

  12. 12.

    Taverna G Giusti G Seveso M Hurle R Colombo P Stifter S Mast cells as a potential prognostic marker in prostate cancer. Dis Markers (2013 ) 35:711–20.

    Not in our library10.1155/2013/478303

  13. 13.

    Xu J Sun J Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl (2013 ) 15:314–22.

    Not in our library10.1038/aja.2013.42

  14. 14.

    Morris MJ Autio KA Basch EM Danila DC Larson S Scher HI. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol (2013 ) 40:375–92.

    Not in our library10.1053/j.seminoncol.2013.04.008

  15. 15.

    Ryan CJ Shah S Efstathiou E Smith MR Taplin ME Bubley GJ Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011 ) 17:4854–61.

    Not in our library10.1158/1078-0432.ccr-11-0815

  16. 16.

    Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012 ) 157:120–34.

    Not in our library10.7326/0003-4819-157-2-201207170-00459

  17. 17.

    Hall MD Schultheiss TE Farino G Wong JYC Increase in higher risk prostate cancer cases following new screening recommendation by the US preventive services task force (USPSTF). J Clin Oncol (2015 ) 33(7 Suppl):143.

    Not in our library

  18. 18.

    Mantovani A Allavena P Sica A Balkwill F. Cancer-related inflammation. Nature (2008 ) 454:436–44.

    Not in our library10.1038/nature07205

  19. 19.

    Kuraishy A Karin M Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity (2011 ) 35:467–77.

    Not in our library10.1016/j.immuni.2011.09.006

  20. 20.

    Vidal AC Howard LE Moreira DM Castro-Santamaria R Andriole GL Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res (2015 ) 21:756–62.

    Not in our library10.1158/1078-0432.ccr-14-2235

  21. 21.

    Bardan R Dumache R Dema A Cumpanas A Bucuras V. The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clin Biochem (2014 ) 47:909–15.

    Not in our library10.1016/j.clinbiochem.2014.02.008

  22. 22.

    De Marzo AM Platz EA Sutcliffe S Xu J Gronberg H Drake CG Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007 ) 7:256–69.

    Not in our library10.1038/nrc2090

  23. 23.

    Elkahwaji JE The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer. Res Rep Urol (2012 ) 5:1–10.

    Not in our library10.2147/rru.s23386

  24. 24.

    Nakai Y Nonomura N Inflammation and prostate carcinogenesis. Int J Urol (2013 ) 20:150–60.

    Not in our library10.1111/j.1442-2042.2012.03101.x

  25. 25.

    Sfanos KS De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology (2012 ) 60:199–215.

    Not in our library10.1111/j.1365-2559.2011.04033.x

  26. 26.

    Vasto S Carruba G Candore G Italiano E Di Bona D Caruso C Inflammation and prostate cancer. Future Oncol (2008 ) 4:637–45.

    Not in our library10.2217/14796694.4.5.637

  27. 27.

    Hsing AW Tsao L Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (2000 ) 85:60–7.

    Not in our library10.1002/(sici)1097-0215(20000101)85:1<60::aid-ijc11>3.0.co;2-b

  28. 28.

    Peto J. Cancer epidemiology in the last century and the next decade. Nature (2001 ) 411:390–5.

    Not in our library10.1038/35077256

  29. 29.

    Davidsson S Fiorentino M Andren O Fang F Mucci LA Varenhorst E Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2011 ) 20:2280–7.

    Not in our library10.1158/1055-9965.epi-11-0373

  30. 30.

    Vral A Magri V Montanari E Gazzano G Gourvas V Marras E Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int J Oncol (2012 ) 41:1950–8.

    Not in our library10.3892/ijo.2012.1646

  31. 31.

    Jiang J Li J Yunxia Z Zhu H Liu J Pumill C. The role of prostatitis in prostate cancer: meta-analysis. PLoS One (2013 ) 8:e85179.

    Not in our library10.1371/journal.pone.0085179

  32. 32.

    Dennis LK Lynch CF Torner JC Epidemiologic association between prostatitis and prostate cancer. Urology (2002 ) 60:78–83.

    Not in our library10.1016/s0090-4295(02)01637-0

  33. 33.

    Irani J Goujon JM Ragni E Peyrat L Hubert J Saint F High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist multi center study group. Urology (1999 ) 54:467–72.

    Not in our library10.1016/s0090-4295(99)00152-1

  34. 34.

    MacLennan GT Eisenberg R Fleshman RL Taylor JM Fu P Resnick MI The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol (2006 ) 176:1012–6.

    Not in our library10.1016/j.juro.2006.04.033

  35. 35.

    Roberts RO Bergstralh EJ Bass SE Lieber MM Jacobsen SJ Prostatitis as a risk factor for prostate cancer. Epidemiology (2004 ) 15:93–9.

    Not in our library10.1097/01.ede.0000101022.38330.7c

  36. 36.

    Engelhardt PF Brustmann H Seklehner S Riedl CR. Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scand J Urol (2013 ) 47:230–5.

    Not in our library10.3109/00365599.2012.733961

  37. 37.

    Gurel B Lucia MS Thompson IM Jr Goodman PJ Tangen CM Kristal AR Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014 ) 23:847–56.

    Not in our library10.1158/1055-9965.epi-13-1126

  38. 38.

    Moreira DM Nickel JC Gerber L Muller RL Andriole GL Castro-Santamaria R Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2014 ) 120:190–6.

    Not in our library10.1002/cncr.28349

  39. 39.

    Pepe P Aragona F. Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int (2011 ) 87:171–4.

    Not in our library10.1159/000328043

  40. 40.

    Yli-Hemminki TH Laurila M Auvinen A Maattanen L Huhtala H Tammela TL Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int (2013 ) 112:735–41.

    Not in our library10.1111/bju.12153

  41. 41.

    Li G Wang H Liu AB Cheung C Reuhl KR Bosland MC Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice. Cancer Prev Res (Phila) (2012 ) 5:963–72.

    Not in our library10.1158/1940-6207.capr-12-0023

  42. 42.

    Boehm BJ Colopy SA Jerde TJ Loftus CJ Bushman W Acute bacterial inflammation of the mouse prostate. Prostate (2012 ) 72:307–17.

    Not in our library10.1002/pros.21433

  43. 43.

    Khalili M Mutton LN Gurel B Hicks JL De Marzo AM Bieberich CJ. Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. Am J Pathol (2010 ) 176:2259–68.

    Not in our library10.2353/ajpath.2010.080747

  44. 44.

    Shinohara DB Vaghasia AM Yu SH Mak TN Bruggemann H Nelson WG A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate (2013 ) 73:1007–15.

    Not in our library10.1002/pros.22648

  45. 45.

    Ammirante M Luo JL Grivennikov S Nedospasov S Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010 ) 464:302–5.

    Not in our library10.1038/nature08782

  46. 46.

    Mercader M Bodner BK Moser MT Kwon PS Park ES Manecke RG T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001 ) 98:14565–70.

    Not in our library10.1073/pnas.251140998

  47. 47.

    Kwon OJ Zhang L Ittmann MM Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2014 ) 111:E592–600.

    Not in our library10.1073/pnas.1318157111

  48. 48.

    Ellem SJ Wang H Poutanen M Risbridger GP. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol (2009 ) 175:1187–99.

    Not in our library10.2353/ajpath.2009.081107

  49. 49.

    Birbach A Eisenbarth D Kozakowski N Ladenhauf E Schmidt-Supprian M Schmid JA. Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia (2011 ) 13:692–703.

    Not in our library10.1593/neo.11524

  50. 50.

    Flammiger A Bayer F Cirugeda-Kuhnert A Huland H Tennstedt P Simon R Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS (2012 ) 120:901–8.

    Not in our library10.1111/j.1600-0463.2012.02924.x

  51. 51.

    Savage PA Vosseller K Kang C Larimore K Riedel E Wojnoonski K Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008 ) 319:215–20.

    Not in our library10.1126/science.1148886

  52. 52.

    Ebelt K Babaryka G Frankenberger B Stief CG Eisenmenger W Kirchner T Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer (2009 ) 45:1664–72.

    Not in our library10.1016/j.ejca.2009.02.015

  53. 53.

    Sfanos KS Bruno TC Meeker AK De Marzo AM Isaacs WB Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009 ) 69:1694–703.

    Not in our library10.1002/pros.21020

  54. 54.
    The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy · 2014
    No notice
  55. 55.

    Gannon PO Poisson AO Delvoye N Lapointe R Mes-Masson AM Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009 ) 348:9–17.

    Not in our library10.1016/j.jim.2009.06.004

  56. 56.

    Nonomura N Takayama H Nakayama M Nakai Y Kawashima A Mukai M Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int (2011 ) 107:1918–22.

    Not in our library10.1111/j.1464-410x.2010.09804.x

  57. 57.

    Escamilla J Schokrpur S Liu C Priceman SJ Moughon D Jiang Z CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res (2015 ) 75:950–62.

    Not in our library10.1158/0008-5472.can-14-0992

  58. 58.

    Valdman A Jaraj SJ Comperat E Charlotte F Roupret M Pisa P Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS (2010 ) 118:360–5.

    Not in our library10.1111/j.1600-0463.2010.02604.x

  59. 59.

    Di Mitri D Toso A Chen JJ Sarti M Pinton S Jost TR Tumour-infiltrating Gr-1 myeloid cells antagonize senescence in cancer. Nature (2014 ) 515(7525):134–7.

    Not in our library10.1038/nature13638

  60. 60.

    Garcia AJ Ruscetti M Arenzana TL Tran LM Bianci-Frias D Sybert E Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol (2014 ) 34:2017–28.

    Not in our library10.1128/mcb.00090-14

  61. 61.

    Idorn M Kollgaard T Kongsted P Sengelov L Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother (2014 ) 63(11):1177–87.

    Not in our library10.1007/s00262-014-1591-2

  62. 62.

    Derhovanessian E Adams V Hahnel K Groeger A Pandha H Ward S Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009 ) 125:1372–9.

    Not in our library10.1002/ijc.24497

  63. 63.

    Johansson A Rudolfsson S Hammarsten P Halin S Pietras K Jones J Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol (2010 ) 177:1031–41.

    Not in our library10.2353/ajpath.2010.100070

  64. 64.

    Pittoni P Tripodo C Piconese S Mauri G Parenza M Rigoni A Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res (2011 ) 71:5987–97.

    Not in our library10.1158/0008-5472.can-11-1637

  65. 65.

    Tang S Moore ML Grayson JM Dubey P. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res (2012 ) 72:1975–85.

    Not in our library10.1158/0008-5472.can-11-2499

  66. 66.

    Ammirante M Shalapour S Kang Y Jamieson CA Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A (2014 ) 111:14776–81.

    Not in our library10.1073/pnas.1416498111

  67. 67.

    Ammirante M Kuraishy AI Shalapour S Strasner A Ramirez-Sanchez C Zhang W An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev (2013 ) 27:1435–40.

    Not in our library10.1101/gad.220202.113

  68. 68.

    Reddy KR Guan Y Qin G Zhou Z Jing N. Combined treatment targeting HIF-1alpha and Stat3 is a potent strategy for prostate cancer therapy. Prostate (2011 ) 71:1796–809.

    Not in our library10.1002/pros.21397

  69. 69.

    Shalapour S Font-Burgada J Di Caro G Zhong Z Wang K Ammirante M Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy. Nature (2015 ) 521(7550):94–8.

    Not in our library10.1038/nature14395

  70. 70.
    Tumor infiltrating B-cells are increased in prostate cancer tissue · 2014
    No notice
  71. 71.

    Dalgleish A Featherstone P Vlassov V Rogosnitzky M. Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature. Invest New Drugs (2014 ) 32:1048–52.

    Not in our library10.1007/s10637-014-0063-z

  72. 72.

    Kantoff PW Higano CS Shore ND Berger ER Small EJ Penson DF Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010 ) 363:411–22.

    Not in our library10.1056/nejmoa1001294

  73. 73.

    Gerritsen WR. The evolving role of immunotherapy in prostate cancer. Ann Oncol (2012 ) 23(Suppl 8):viii22–7.

    Not in our library10.1093/annonc/mds259

  74. 74.

    Rigamonti N Bellone M. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother (2012 ) 61:453–68.

    Not in our library10.1007/s00262-012-1216-6

  75. 75.

    Simons JW Mikhak B Chang JF DeMarzo AM Carducci MA Lim M Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res (1999 ) 59:5160–8.

    Not in our library

  76. 76.

    Simons JW Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol (2006 ) 24:419–24.

    Not in our library10.1016/j.urolonc.2005.08.021

  77. 77.

    Small EJ Fratesi P Reese DM Strang G Laus R Peshwa MV Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000 ) 18:3894–903.

    Not in our library10.1200/jco.2000.18.23.3894

  78. 78.

    Jochems C Tucker JA Tsang KY Madan RA Dahut WL Liewehr DJ A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014 ) 63:407–18.

    Not in our library10.1007/s00262-014-1524-0

  79. 79.

    Klyushnenkova EN Riabov VB Kouiavskaia DV Wietsma A Zhan M Alexander RB. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate (2014 ) 74:1423–32.

    Not in our library10.1002/pros.22858

  80. 80.

    Fujii T Shimada K Asai O Tanaka N Fujimoto K Hirao K Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology (2013 ) 80:119–26.

    Not in our library10.1159/000342396

  81. 81.

    Yuan H Hsiao YH Zhang Y Wang J Yin C Shen R Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer (2013 ) 13:258.

    Not in our library10.1186/1471-2407-13-258

  82. 82.

    Sfanos KS Bruno TC Maris CH Xu L Thoburn CJ DeMarzo AM Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008 ) 14:3254–61.

    Not in our library10.1158/1078-0432.ccr-07-5164

  83. 83.

    Gollapudi K Galet C Grogan T Zhang H Said JW Huang J Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res (2013 ) 3:523–9.

    Not in our library

  84. 84.

    Craig M Ying C Loberg RD. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J Cell Biochem (2008 ) 103:1–8.

    Not in our library10.1002/jcb.21379

  85. 85.

    Fleischmann A Schlomm T Kollermann J Sekulic N Huland H Mirlacher M Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate (2009 ) 69:976–81.

    Not in our library10.1002/pros.20948

  86. 86.

    Sonpavde G Pond GR Armstrong AJ Clarke SJ Vardy JL Templeton AJ Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2014 ) 12:317–24.

    Not in our library10.1016/j.clgc.2014.03.005

  87. 87.

    Fujita K Imamura R Tanigawa G Nakagawa M Hayashi T Kishimoto N Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis (2012 ) 15:386–90.

    Not in our library10.1038/pcan.2012.27

  88. 88.

    Sumbul AT Sezer A Abali H Kose F Gultepe I Mertsoylu H Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol (2014 ) 46:1531–5.

    Not in our library10.1007/s11255-014-0664-7

  89. 89.

    Templeton AJ Pezaro C Omlin A McNamara MG Leibowitz-Amit R Vera-Badillo FE Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014 ) 120(21):3346–52.

    Not in our library10.1002/cncr.28890

  90. 90.

    Nuhn P Vaghasia AM Goyal J Zhou XC Carducci MA Eisenberger MA Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int (2013 ) 114:E11–7.

    Not in our library10.1111/bju.12531

  91. 91.

    Shafique K Proctor MJ McMillan DC Qureshi K Leung H Morrison DS. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow inflammation outcome study. Prostate Cancer Prostatic Dis (2012 ) 15:195–201.

    Not in our library10.1038/pcan.2011.60

  92. 92.

    Sadeghi N Badalato GM Hruby G Grann V McKiernan JM. Does absolute neutrophil count predict high tumor grade in African-American men with prostate cancer? Prostate (2012 ) 72:386–91.

    Not in our library10.1002/pros.21440

  93. 93.
    A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer · 2006
    No notice
  94. 94.
    Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer · 2014
    Not checked
  95. 95.

    Kwon ED Drake CG Scher HI Fizazi K Bossi A van den Eertwegh AJ Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014 ) 15:700–12.

    Not in our library10.1016/s1470-2045(14)70189-5

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.